ALICIA CONWAY: Open Payments
NPI 1689140485 · STOCKTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$587 in 22 payments from 8 companies in 2025. Trend: 2023 $182 · 2024 $0 · 2025 $587
Food & beverage: $555Education: $32
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 11 | $278 |
| Novartis Pharmaceuticals Corporation | 2 | $68 |
| Novo Nordisk Inc | 2 | $67 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $49 |
| ABBVIE INC. | 2 | $42 |
| ABIOMED | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
Products named: Korlym, LEQVIO, XIFAXAN, Ozempic, LINZESS, ENTYVIO, RECORLEV, QULIPTA.
Industry payments across CA — which companies pay providers there.
